Healthcare

Precigen reports PAPZIMEOS revenue of $72.9 million in third quarter

Precigen said PAPZIMEOS net revenue rose 37% sequentially in the third quarter, while the company reported positive cash flow and continued pipeline development.

Published:
Reading Time
3 min

Precigen Inc. (Nasdaq:PGEN) reported PAPZIMEOS net revenue of $72.9 million for the third quarter, up 37% sequentially. The company also reported net income of $35.8 million, or $0.08 per diluted share, and said it achieved positive cash flow a quarter ahead of schedule.

#Third-quarter financial results

Precigen said the period was its second consecutive profitable period. Cash, cash equivalents and investments stood at $51 million, while cumulative product revenue since the launch of PAPZIMEOS reached approximately $151 million.

The results were reported on November 10, 2026. The company attributed the performance to continued uptake of PAPZIMEOS, its treatment for adults with recurrent respiratory papillomatosis (RRP).

#PAPZIMEOS treatment uptake

More than 500 patients had begun PAPZIMEOS treatment since its August 2025 approval, according to Precigen, and more than 300 patients had completed therapy.

The company said use was expanding across academic medical centres, infusion centres and community practices. Precigen also cited payer coverage for more than 315 million US lives, a permanent J-code and clinical data as factors supporting adoption.

RRP causes recurring airway tumours and has traditionally been treated through repeated surgeries. Precigen describes PAPZIMEOS as the first FDA-approved therapy for adults with the condition.

#Clinical data and competing therapy

Precigen said PAPZIMEOS recorded a 51% complete response rate in its pivotal trial. The company defines a complete response as requiring no surgeries during the year following treatment.

Data presented at the American Academy of Otolaryngology-Head and Neck Surgery Foundation annual meeting showed ongoing complete responses for up to five years after treatment, according to the company. Precigen also said the pivotal trial recorded no treatment-related adverse events above Grade 2 and no dose-limiting toxicities.

A second RRP treatment recently received conditional FDA approval, Precigen said. That approval requires a confirmatory study to establish clinical benefit and used a surrogate endpoint based on reducing surgeries rather than the current standard of complete response.

Precigen said the competing product is anticipated to arrive at least a year and a half behind PAPZIMEOS and has an electroporation device with open FDA commitments. The company said the introduction of another therapy had been incorporated into its strategic planning, commercial modelling and investment decisions.

#AdenoVerse platform and PRGN-2009

In September, Precigen said it received an FDA Platform Technology Designation for its AdenoVerse technology platform. The company said the designation could shorten development timelines for future programmes by allowing existing manufacturing and preclinical data to be used across multiple product candidates.

PRGN-2009 uses the same AdenoVerse vector backbone as PAPZIMEOS and is in Phase 2 trials for cancers associated with HPV 16 and HPV 18. One study is evaluating PRGN-2009 with pembrolizumab in newly diagnosed HPV oropharyngeal cancer in a neoadjuvant setting. A separate multicentre study is assessing the combination in recurrent or metastatic cervical cancer.

Precigen said a data update for the head and neck programme is expected at a forthcoming R&D Day.

#Additional development plans

Management identified several further development areas for PAPZIMEOS and the wider pipeline. These include a redosing study examining whether partial responders can transition into complete responders, paediatric development efforts and European expansion.

Regulators are reviewing PAPZIMEOS' marketing application in Europe. Precigen also said it would continue developing PRGN-2009.

#Key Takeaways

  • PAPZIMEOS net revenue was $72.9 million in the third quarter, up 37% sequentially.
  • Precigen reported net income of $35.8 million, or $0.08 per diluted share, and positive cash flow a quarter ahead of schedule.
  • More than 500 patients had started PAPZIMEOS treatment since its August 2025 approval, with more than 300 completing therapy.
  • The company reported a 51% complete response rate in its pivotal trial and ongoing complete responses for up to five years after treatment.
  • Precigen is pursuing PAPZIMEOS redosing and paediatric programmes, European expansion and continued development of PRGN-2009.

Original source: Read original article

Frequently Asked Questions